Cell and Biologic-Based Treatment of Flexor Tendon Injuries.
Cell and Biologic-Based Treatment of Flexor Tendon Injuries.
复制标题
DOI：
10.1053/j.oto.2016.06.011
复制
发表时间：
2016-09
影响因子：
0.1
通讯作者：
Shen H
中科院分区：
文献类型：
--
作者：
Linderman SW;Gelberman RH;Thomopoulos S;Shen H
导致滑膜内肌腱修复后临床效果不佳的两个主要因素是指鞘内粘连形成和修复部位伸长和断裂。由于现代肌腱多股修复和受控康复技术的结果往往不令人满意，替代方法，如应用生长因子和间充质干细胞（MSC），已成为越来越有吸引力的治疗选择。成功的生物疗法需要仔细控制细胞、生长因子和生物相容性支架基质的时空递送，以便同时（1）促进肌腱修复部位的基质合成，从而增加生物力学强度和刚度，以及（2）抑制基质合成沿着肌腱表面和滑液鞘，防止粘连形成。本文综述了最近的细胞和生物为基础的实验治疗屈肌腱损伤，重点是大型动物的翻译研究。
The two primary factors leading to poor clinical results after intrasynovial tendon repair are adhesion formation within the digital sheath and repair-site elongation and rupture. As the outcomes following modern tendon multi-strand repair and controlled rehabilitation techniques are often unsatisfactory, alternative approaches, such as the application of growth factors and mesenchymal stem cells (MSCs), have become increasingly attractive treatment options. Successful biological therapies require carefully controlled spatiotemporal delivery of cells, growth factors, and biocompatible scaffold matrices in order to simultaneously (1) promote matrix synthesis at the tendon repair site leading to increased biomechanical strength and stiffness and (2) suppress matrix synthesis along the tendon surface and synovial sheath preventing adhesion formation. This review summarizes recent cell and biologic-based experimental treatments for flexor tendon injury, with an emphasis on large animal translational studies.